Daily Dilution Report - Apr 17, 2026
All Events
$YORW (MC: $437M)
- Direct Offering for 1.52M shares @ $28.50/share ($43.4M).
- Underwriter has option for 228K additional shares @ $28.50/share, expiring within 30 days from 4/16/26.
$PCT (MC: $1.2B)
- PCT Warrants: Expiration date extended from June 17, 2026, to March 17, 2027.
- PCT Warrants: Redemption trigger price reduced from $18.00/share to $14.38/share.
- These amended terms for approx. 4.0M warrants can increase the likelihood of future dilution.
$GYRE (MC: $721M)
- All-stock merger agreement to acquire Cullgen for ~$300M, issuing Common Stock and Series B Convertible Preferred Stock.
- Series B Convertible Preferred Stock is convertible into 5 shares of Common Stock per preferred share.
- Total issuance limited to 19.99% of O/S Common Stock or voting power prior to Conversion Proposal approval.
$VACI (MC: $314M)
- Business Combination Agreement: 30M New Viking common shares to be issued to equityholders; up to 10M earnout shares contingent on future targets.
- PIPE Financing: $30M in New Viking Shares + warrants to acquire 3M New Viking Shares.
- New Viking Equity Plan: Reserves 10% of post-closing fully diluted shares for issuance.
$OSUR (MC: $222M)
- $100K stock award to new director (restricted shares).
- Vests over 2 years, contributes to dilution over time.
$YORW (MC: $436M)
- Direct Offering: 1.52M shares at $28.50/share (total ~$43.4M). Delivery expected Apr 17, 2026.
- Underwriter over-allotment option for up to 228K additional shares at $28.50.
- Shelf Registration: up to $60M for future common stock and debt securities offerings.
$TE (MC: $866M)
- New $160M 4.00% Convertible Senior Notes due 2031, convertible at ~$6.80/share (~23.5M potential shares). Underwriters have a $24M over-allotment option.
- Existing $161M 5.25% Convertible Senior Notes due 2030, convertible at ~$6.93/share (~23.2M potential shares). Also, 4.27M shares issued @ $1.70 (Trina) & 7M shares @ $0.01 (Stellar Hann).
- Series B & B-1 Convertible Preferred Stock potentially converting to up to ~38.8M common shares. Warrants for ~24.6M shares exercisable @ $11.50/share.
$MGTX (MC: $772M)
- Direct Offering: 11.11M shares sold at $9.00/share, raising $100M.
- $100M ATM program in place; currently cannot issue shares for 30 days post-April 16, 2026.
- $250M shelf registration filed for future offerings; 0.7M warrants @ $8.00.
$MGTX (MC: $772M)
- Direct Offering of 11.1M shares at $9.00/share.
- Gross proceeds $100M, net proceeds $93.3M.
$ISBA (MC: $362M)
- Stock Compensation Plans: 62,901 shares of common stock reserved for future issuance under equity incentive plans as of April 14, 2026.
$TRVI (MC: $1.9B)
- Direct Offering: $150M of common stock, plus $22.5M over-allotment option.
- ATM program up to $200M. Sold $14.6M from 4.5M shares as of April 15, 2026.
- Warrants for 1.85M shares @ $1.37; 17.2M pre-funded warrants @ $0.001. 5M authorized preferred stock.
$ACHV (MC: $256M)
- Private Placement raised ~$180M via ~49.4M shares and ~49.5M common warrants.
- Common Warrants for ~49.5M shares (exercise $3.51) issued, exercisable upon FDA approval, potential ~$173.8M.
- Equity awards for CEO (9.5% of fully diluted cap post-placement) and director stock options to be issued.